Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Das Thema chronische Unterbauch- und Viszeralschmerzen wird im Live-Webinar am 7. Mai von 17.30 bis 19 Uhr aus internistischer, gynäkologischer und psychologisch-neurowissenschaftlicher Perspektive beleuchtet. Besprochen werden krankheitsbedingte Ursachen, Mechanismen der kognitiven Schmerzmodulation sowie mögliche Therapieoptionen. Die Fortbildung ist mit 2 CME-Punkten zertifiziert. Melden Sie sich jetzt an!
Erweiterte Suche
Anmelden
nach oben
Current Neurology and Neuroscience Reports
Erschienen in: Current Neurology and Neuroscience Reports 5/2013

01.05.2013 | Neuro-Oncology (LE Abrey, Section Editor)

Brainstem Glioma: A Review

verfasst von: Sean A. Grimm, Marc C. Chamberlain

Erschienen in: Current Neurology and Neuroscience Reports | Ausgabe 5/2013

Einloggen, um Zugang zu erhalten

Abstract

Brainstem gliomas (BGs) are a heterogenous group of gliomas that occur predominately in children. They can be separated into groups on the basis of anatomy and clinical behavior: diffuse intrinsic pontine glioma (DIPG), exophytic medullary glioma, and tectal glioma. DIPG is the commonest BG. Median age at onset is 6.5 years and median survival is less than 1 year. Adults with DIPG survive longer, suggesting a less aggressive and biologically different tumor from that in children. Patients present with cranial nerve dysfunction, long tract signs, or ataxia, either in isolation or in combination. Magnetic resonance imaging shows an infiltrative lesion occupying most of the pons and contrast enhancement is usually not prominent. Standard treatment is fractionated radiotherapy. Platelet-derived growth factor receptor alpha and epidermal growth factor receptor mutations have been identified. Inhibitors of these growth factor receptors are being evaluated in clinical trials. Exophytic medullary and tectal gliomas are relatively indolent tumors that can often be followed closely without treatment.
Literatur
1.
Dolecek TA et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005–2009. Neuro Oncol. 2012;14 Suppl 5:v1–49.PubMedCrossRef
2.
Smith MA et al. Trends in reported incidence of primary malignant brain tumors in children in the United States. J Natl Cancer Inst. 1998;90(17):1269–77.PubMedCrossRef
3.
Fisher PG et al. A clinicopathologic reappraisal of brain stem tumor classification. Identification of pilocystic astrocytoma and fibrillary astrocytoma as distinct entities. Cancer. 2000;89(7):1569–76.PubMedCrossRef
4.
Donaldson SS, Laningham F, Fisher PG. Advances toward an understanding of brainstem gliomas. J Clin Oncol. 2006;24(8):1266–72.PubMedCrossRef
5.
Hargrave D, Bartels U, Bouffet E. Diffuse brainstem glioma in children: critical review of clinical trials. Lancet Oncol. 2006;7(3):241–8.PubMedCrossRef
6.
Sun T et al. Clinical outcomes and natural history of pediatric brainstem tumors: with 33 cases follow-ups. Neurosurg Rev, 2012.
7.
Yoshimura J et al. Clinicopathological study of diffuse type brainstem gliomas: analysis of 40 autopsy cases. Neurol Med Chir (Tokyo). 2003;43(8):375–82. discussion 382.CrossRef
8.
Fangusaro J. Pediatric high-grade gliomas and diffuse intrinsic pontine gliomas. J Child Neurol. 2009;24(11):1409–17.PubMedCrossRef
9.
•• Bartels U et al. Proceedings of the diffuse intrinsic pontine glioma (DIPG) Toronto Think Tank: advancing basic and translational research and cooperation in DIPG. J Neurooncol. 2011;105(1):119–25. This is a transcript of a meeting of DIDG experts that discusses state-of-the-art treatment and basic/translational research in the field.PubMedCrossRef
10.
•• Zarghooni M et al. Whole-genome profiling of pediatric diffuse intrinsic pontine gliomas highlights platelet-derived growth factor receptor alpha and poly (ADP-ribose) polymerase as potential therapeutic targets. J Clin Oncol. 2010;28(8):1337–44. This is a DNA microarray study that identified a potential target for the treatment of DIPG.PubMedCrossRef
11.
•• Paugh BS et al. Genome-wide analyses identify recurrent amplifications of receptor tyrosine kinases and cell-cycle regulatory genes in diffuse intrinsic pontine glioma. J Clin Oncol. 2011;29(30):3999–4006. This is a DNA microarray study that identified potential treatment targets for DIPG.PubMedCrossRef
12.
•• Sturm D et al. Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell. 2012;22(4):425–37. This article discusses genetic mutations frequently found in DIPGs.PubMedCrossRef
13.
Gilbertson RJ et al. ERBB1 is amplified and overexpressed in high-grade diffusely infiltrative pediatric brain stem glioma. Clin Cancer Res. 2003;9(10 Pt 1):3620–4.PubMed
14.
Li G et al. Expression of epidermal growth factor variant III (EGFRvIII) in pediatric diffuse intrinsic pontine gliomas. J Neurooncol. 2012;108(3):395–402.PubMedCrossRef
15.
Mandell LR et al. There is no role for hyperfractionated radiotherapy in the management of children with newly diagnosed diffuse intrinsic brainstem tumors: results of a Pediatric Oncology Group phase III trial comparing conventional vs. hyperfractionated radiotherapy. Int J Radiat Oncol Biol Phys. 1999;43(5):959–64.PubMedCrossRef
16.
Janssens GO et al. Hypofractionation vs conventional radiation therapy for newly diagnosed diffuse intrinsic pontine glioma: a matched-cohort analysis. Int J Radiat Oncol Biol Phys, 2012.
17.
Janssens GO et al. The role of hypofractionation radiotherapy for diffuse intrinsic brainstem glioma in children: a pilot study. Int J Radiat Oncol Biol Phys. 2009;73(3):722–6.PubMedCrossRef
18.
Allen J et al. A phase I/II study of carboplatin combined with hyperfractionated radiotherapy for brainstem gliomas. Cancer. 1999;86(6):1064–9.PubMedCrossRef
19.
Freeman CR et al. A detrimental effect of a combined chemotherapy-radiotherapy approach in children with diffuse intrinsic brain stem gliomas? Int J Radiat Oncol Biol Phys. 2000;47(3):561–4.PubMedCrossRef
20.
• Chassot A et al. Radiotherapy with concurrent and adjuvant temozolomide in children with newly diagnosed diffuse intrinsic pontine glioma. J Neurooncol. 2012;106(2):399–407. No benefit was found from the addition of TMZ to RT for the treatment of DIPG.PubMedCrossRef
21.
• Cohen KJ et al. Temozolomide in the treatment of children with newly diagnosed diffuse intrinsic pontine gliomas: a report from the Children's Oncology Group. Neuro Oncol. 2011;13(4):410–6. No benefit was found from the addition of TMZ to RT for the treatment of DIPG.PubMedCrossRef
22.
Jalali R et al. Prospective evaluation of radiotherapy with concurrent and adjuvant temozolomide in children with newly diagnosed diffuse intrinsic pontine glioma. Int J Radiat Oncol Biol Phys. 2010;77(1):113–8.PubMedCrossRef
23.
Sharp JR et al. A multi-centre Canadian pilot study of metronomic temozolomide combined with radiotherapy for newly diagnosed paediatric brainstem glioma. Eur J Cancer. 2010;46(18):3271–9.PubMedCrossRef
24.
Bernier-Chastagner V et al. Topotecan as a radiosensitizer in the treatment of children with malignant diffuse brainstem gliomas: results of a French Society of Paediatric Oncology phase II study. Cancer. 2005;104(12):2792–7.PubMedCrossRef
25.
Bradley KA et al. Motexafin-gadolinium and involved field radiation therapy for intrinsic pontine glioma of childhood: a Children's Oncology Group phase 2 study. Int J Radiat Oncol Biol Phys. 2013;85(1):e55–60.PubMedCrossRef
26.
Sirachainan N et al. Concurrent radiotherapy with temozolomide followed by adjuvant temozolomide and cis-retinoic acid in children with diffuse intrinsic pontine glioma. Neuro Oncol. 2008;10(4):577–82.PubMedCrossRef
27.
Freeman CR, Perilongo G. Chemotherapy for brain stem gliomas. Childs Nerv Syst. 1999;15(10):545–53.PubMedCrossRef
28.
Gururangan S et al. Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a Pediatric Brain Tumor Consortium study. J Clin Oncol. 2010;28(18):3069–75.PubMedCrossRef
29.
Wolff JE et al. Treatment of recurrent diffuse intrinsic pontine glioma: the MD Anderson Cancer Center experience. J Neurooncol. 2012;106(2):391–7.PubMedCrossRef
30.
Pollack IF et al. A phase II study of gefitinib and irradiation in children with newly diagnosed brainstem gliomas: a report from the Pediatric Brain Tumor Consortium. Neuro Oncol. 2011;13(3):290–7.PubMedCrossRef
31.
Aguilar LK et al. The spectrum of vaccine therapies for patients with glioblastoma multiforme. Curr Treat Options Oncol. 2012;13(4):437–50.PubMedCrossRef
32.
33.
Squires LA et al. Focal tectal tumors: management and prognosis. Neurology. 1994;44(5):953–6.PubMedCrossRef
34.
Bognar L et al. Tectal plate gliomas. Part II: CT scans and MR imaging of tectal gliomas. Acta Neurochir (Wien). 1994;127(1–2):48–54.CrossRef
35.
Bowers DC et al. Tectal gliomas: natural history of an indolent lesion in pediatric patients. Pediatr Neurosurg. 2000;32(1):24–9.PubMedCrossRef
36.
Pollack IF, Pang D, Albright AL. The long-term outcome in children with late-onset aqueductal stenosis resulting from benign intrinsic tectal tumors. J Neurosurg. 1994;80(4):681–8.PubMedCrossRef
37.
Wellons 3rd JC et al. Long-term control of hydrocephalus via endoscopic third ventriculostomy in children with tectal plate gliomas. Neurosurgery. 2002;51(1):63–7. discussion 67–8.PubMedCrossRef
38.
Yeh DD, Warnick RE, Ernst RJ. Management strategy for adult patients with dorsal midbrain gliomas. Neurosurgery. 2002;50(4):735–8. discussion 738–40.PubMedCrossRef
39.
Jallo GI, Biser-Rohrbaugh A, Freed D. Brainstem gliomas. Childs Nerv Syst. 2004;20(3):143–53.PubMedCrossRef
40.
Freeman CR, Farmer JP. Pediatric brain stem gliomas: a review. Int J Radiat Oncol Biol Phys. 1998;40(2):265–71.PubMedCrossRef
41.
Zimmerman RA. Neuroimaging of primary brainstem gliomas: diagnosis and course. Pediatr Neurosurg. 1996;25(1):45–53.PubMedCrossRef
42.
Khatib ZA et al. Predominance of pilocytic histology in dorsally exophytic brain stem tumors. Pediatr Neurosurg. 1994;20(1):2–10.PubMedCrossRef
43.
Pollack IF et al. The long-term outcome after surgical treatment of dorsally exophytic brain-stem gliomas. J Neurosurg. 1993;78(6):859–63.PubMedCrossRef
44.
Landolfi JC, Thaler HT, DeAngelis LM. Adult brainstem gliomas. Neurology. 1998;51(4):1136–9.PubMedCrossRef
45.
Guillamo JS et al. Brainstem gliomas in adults: prognostic factors and classification. Brain. 2001;124(Pt 12):2528–39.PubMedCrossRef
46.
Levin VA et al. 5-Fluorouracil and 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) followed by hydroxyurea, misonidazole, and irradiation for brain stem gliomas: a pilot study of the Brain Tumor Research Center and the Childrens Cancer Group. Neurosurgery. 1984;14(6):679–81.PubMedCrossRef
47.
Jenkin RD et al. Brain-stem tumors in childhood: a prospective randomized trial of irradiation with and without adjuvant CCNU, VCR, and prednisone. A report of the Childrens Cancer Study Group. J Neurosurg. 1987;66(2):227–33.PubMedCrossRef
48.
Kretschmar CS et al. Pre-irradiation chemotherapy and hyperfractionated radiation therapy 66 Gy for children with brain stem tumors. A phase II study of the Pediatric Oncology Group, protocol 8833. Cancer. 1993;72(4):1404–13.PubMedCrossRef
49.
Jennings MT et al. Preradiation chemotherapy in primary high-risk brainstem tumors: phase II study CCG-9941 of the Children's Cancer Group. J Clin Oncol. 2002;20(16):3431–7.PubMedCrossRef
50.
Korones DN et al. Treatment of children with diffuse intrinsic brain stem glioma with radiotherapy, vincristine and oral VP-16: a Children's Oncology Group phase II study. Pediatr Blood Cancer. 2008;50(2):227–30.PubMedCrossRef
51.
Kim CY et al. A prospective study of temozolomide plus thalidomide during and after radiation therapy for pediatric diffuse pontine gliomas: preliminary results of the Korean Society for Pediatric Neuro-Oncology study. J Neurooncol. 2010;100(2):193–8.PubMedCrossRef
52.
Wolff JE et al. High dose methotrexate for pediatric high grade glioma: results of the HIT-GBM-D pilot study. J Neurooncol. 2011;102(3):433–42.PubMedCrossRef
53.
Haas-Kogan DA et al. Phase II trial of tipifarnib and radiation in children with newly diagnosed diffuse intrinsic pontine gliomas. Neuro Oncol. 2011;13(3):298–306.PubMedCrossRef
54.
Massimino M et al. Nimotuzumab for pediatric diffuse intrinsic pontine gliomas. Expert Opin Biol Ther. 2011;11(2):247–56.PubMedCrossRef
55.
Warren K et al. A phase 2 study of pegylated interferon alpha-2b (PEG-Intron((R))) in children with diffuse intrinsic pontine glioma. Cancer. 2012;118(14):3607–13.PubMedCrossRef
56.
Pollack IF et al. Phase I trial of imatinib in children with newly diagnosed brainstem and recurrent malignant gliomas: a Pediatric Brain Tumor Consortium report. Neuro Oncol. 2007;9(2):145–60.PubMedCrossRef
57.
Fouladi M et al. Phase I trial of lapatinib in children with refractory CNS malignancies: a Pediatric Brain Tumor Consortium study. J Clin Oncol. 2010;28(27):4221–7.PubMedCrossRef
58.
Broniscer A et al. Phase I study of vandetanib during and after radiotherapy in children with diffuse intrinsic pontine glioma. J Clin Oncol. 2010;28(31):4762–8.PubMedCrossRef
59.
Geyer JR et al. A phase I and biology study of gefitinib and radiation in children with newly diagnosed brain stem gliomas or supratentorial malignant gliomas. Eur J Cancer. 2010;46(18):3287–93.PubMedCrossRef
60.
Geoerger B et al. Innovative therapies for children with cancer pediatric phase I study of erlotinib in brainstem glioma and relapsing/refractory brain tumors. Neuro Oncol. 2011;13(1):109–18.PubMedCrossRef
Metadaten
Titel
Brainstem Glioma: A Review
verfasst von
Sean A. Grimm
Marc C. Chamberlain
Publikationsdatum
01.05.2013
Verlag
Current Science Inc.
Erschienen in
Current Neurology and Neuroscience Reports / Ausgabe 5/2013
Print ISSN: 1528-4042
Elektronische ISSN: 1534-6293
DOI
https://doi.org/10.1007/s11910-013-0346-3

Weitere Artikel der Ausgabe 5/2013

Current Neurology and Neuroscience Reports 5/2013 Zur Ausgabe

Epilepsy (CW Bazil, Section Editor)

Antibodies in Epilepsy

Neuro-Oncology (LE Abrey, Section Editor)

Management of Elderly Patients with Primary Central Nervous System Lymphoma

Sleep (M Thorpy and M Billiard, Section Editors)

Neuroimaging Findings in Narcolepsy with Cataplexy

Neuro-Oncology (LE Abrey, Section Editor)

Response Assessment Criteria for Glioblastoma: Practical Adaptation and Implementation in Clinical Trials of Antiangiogenic Therapy

Neuro-Oncology (LE Abrey, Section Editor)

IDH1 and IDH2 Mutations in Gliomas

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Stuhltransfusion könnte Fortschreiten von Parkinson-Symptomen bremsen

03.05.2024 Parkinson-Krankheit Nachrichten

Kann eine frühzeitige Stuhltransplantation das Fortschreiten von Parkinson-Symptomen verlangsamen? Die Ergebnisse einer randomisierten Phase-2-Studie scheinen dafür zu sprechen.

Frühe Tranexamsäure-Therapie nützt wenig bei Hirnblutungen

02.05.2024 Hirnblutung Nachrichten

Erhalten Personen mit einer spontanen Hirnblutung innerhalb von zwei Stunden nach Symptombeginn eine Tranexamsäure-Therapie, kann dies weder die Hämatomexpansion eindämmen noch die Mortalität senken.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders scheint das auf weibliche Kranke zuzutreffen, wie eine Studie zeigt.

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise